Literature DB >> 17377509

Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery.

M K Sinha1, M L Collazo-Clavell, A Rule, D S Milliner, W Nelson, M G Sarr, R Kumar, J C Lieske.   

Abstract

Roux-en-Y bypass surgery is the most common bariatric procedure currently performed in the United States for medically complicated obesity. Although this leads to a marked and sustained weight loss, we have identified an increasing number of patients with episodes of nephrolithiasis afterwards. We describe a case series of 60 patients seen at Mayo Clinic-Rochester that developed nephrolithiasis after Roux-en-Y gastric bypass (RYGB), including a subset of 31 patients who had undergone metabolic evaluation in the Mayo Stone Clinic. The mean body mass index of the patients before procedure was 57 kg/m(2) with a mean decrease of 20 kg/m(2) at the time of the stone event, which averaged 2.2 years post-procedure. When analyzed, calcium oxalate stones were found in 19 and mixed calcium oxalate/uric acid stones in two patients. Hyperoxaluria was a prevalent factor even in patients without a prior history of nephrolithiasis, and usually presented more than 6 months after the procedure. Calcium oxalate supersaturation, however, was equally high in patients less than 6 months post-procedure due to lower urine volumes. In a small random sampling of patients undergoing this bypass procedure, hyperoxaluria was rare preoperatively but common 12 months after surgery. We conclude that hyperoxaluria is a potential complicating factor of RYGB surgery manifested as a risk for calcium oxalate stones.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17377509     DOI: 10.1038/sj.ki.5002194

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  76 in total

1.  The effects of bariatric surgery on the kidneys.

Authors:  Dean G Assimos
Journal:  Rev Urol       Date:  2010

2.  Evidence for net renal tubule oxalate secretion in patients with calcium kidney stones.

Authors:  Kristin J Bergsland; Anna L Zisman; John R Asplin; Elaine M Worcester; Fredric L Coe
Journal:  Am J Physiol Renal Physiol       Date:  2010-12-01

3.  Clinical characteristics of potential kidney donors with asymptomatic kidney stones.

Authors:  Elizabeth C Lorenz; John C Lieske; Terri J Vrtiska; Amy E Krambeck; Xujian Li; Eric J Bergstralh; L Joseph Melton; Andrew D Rule
Journal:  Nephrol Dial Transplant       Date:  2011-02-01       Impact factor: 5.992

Review 4.  Kidney stone risk following modern bariatric surgery.

Authors:  Ricardo D Gonzalez; Benjamin K Canales
Journal:  Curr Urol Rep       Date:  2014-05       Impact factor: 3.092

Review 5.  Urinary stone disease and obesity: Different pathologies sharing common biochemical mechanisms.

Authors:  Ozgu Aydogdu
Journal:  World J Nephrol       Date:  2012-02-06

6.  Genetically engineered Lactobacillus plantarum WCFS1 constitutively secreting heterologous oxalate decarboxylase and degrading oxalate under in vitro.

Authors:  Ponnusamy Sasikumar; Sivasamy Gomathi; Kolandaswamy Anbazhagan; A Ebenezer Baby; J Sangeetha; Govindan Sadasivam Selvam
Journal:  Curr Microbiol       Date:  2014-07-03       Impact factor: 2.188

7.  Obesity and kidney disease: hidden consequences of the epidemic.

Authors:  Csaba P Kovesdy; Susan L Furth; Carmine Zoccali
Journal:  Pediatr Nephrol       Date:  2017-02-01       Impact factor: 3.714

8.  Use of sevelamer hydrochloride as an oxalate binder.

Authors:  John C Lieske; Cynthia Regnier; John J Dillon
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

Review 9.  Update on the surgical management of idiopathic intracranial hypertension.

Authors:  Nisha Mukherjee; M Tariq Bhatti
Journal:  Curr Neurol Neurosci Rep       Date:  2014-03       Impact factor: 5.081

Review 10.  Hyperoxaluria after modern bariatric surgery: case series and literature review.

Authors:  Jared M Whitson; G Bennett Stackhouse; Marshall L Stoller
Journal:  Int Urol Nephrol       Date:  2009-07-02       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.